Bio-Rad Laboratories, Inc. $BIO Shares Sold by Moore Capital Management LP

Moore Capital Management LP decreased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 9.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,000 shares of the medical research company’s stock after selling 5,000 shares during the quarter. Moore Capital Management LP owned 0.19% of Bio-Rad Laboratories worth $15,150,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Natixis Advisors LLC grew its position in Bio-Rad Laboratories by 67.1% in the third quarter. Natixis Advisors LLC now owns 65,069 shares of the medical research company’s stock valued at $18,245,000 after acquiring an additional 26,119 shares in the last quarter. Mangrove Partners IM LLC acquired a new stake in shares of Bio-Rad Laboratories during the third quarter worth approximately $35,568,000. Gotham Asset Management LLC grew its position in shares of Bio-Rad Laboratories by 41.8% during the third quarter. Gotham Asset Management LLC now owns 124,626 shares of the medical research company’s stock worth $34,944,000 after buying an additional 36,763 shares in the last quarter. TD Asset Management Inc grew its position in shares of Bio-Rad Laboratories by 461.0% during the third quarter. TD Asset Management Inc now owns 8,988 shares of the medical research company’s stock worth $2,520,000 after buying an additional 7,386 shares in the last quarter. Finally, Magnetar Financial LLC acquired a new stake in shares of Bio-Rad Laboratories during the third quarter worth approximately $2,923,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Citigroup downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $375.00 to $300.00 in a research report on Tuesday, April 7th. Royal Bank Of Canada assumed coverage on shares of Bio-Rad Laboratories in a research report on Friday, May 15th. They set an “outperform” rating and a $320.00 price target for the company. Wells Fargo & Company decreased their price target on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating for the company in a research report on Friday, May 1st. Finally, Weiss Ratings downgraded shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 6th. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Bio-Rad Laboratories presently has a consensus rating of “Hold” and a consensus target price of $303.33.

Bio-Rad Laboratories Stock Performance

Shares of BIO opened at $284.77 on Thursday. The business’s fifty day moving average price is $284.41 and its 200 day moving average price is $290.07. Bio-Rad Laboratories, Inc. has a 12-month low of $228.40 and a 12-month high of $343.12. The stock has a market capitalization of $7.62 billion, a PE ratio of 46.91 and a beta of 1.08. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.21 and a quick ratio of 2.37.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $1.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.97 by ($0.08). Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The firm had revenue of $592.10 million for the quarter, compared to the consensus estimate of $589.91 million. During the same quarter last year, the business earned $2.54 earnings per share. The business’s revenue for the quarter was up 1.1% compared to the same quarter last year. Equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 9.42 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.